Celcuity (CELC) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celcuity Reports Third Quarter Fiscal 2017 Financial Results
November 13, 2017 7:00 AM ESTMINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (NASDAQ: CELC) a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the third quarter ended September 30, 2017.
Unless otherwise stated, all comparisons are for the third quarter and nine months ended September 30, 2017, compared to the third quarter and nine months ended September 30, 2016.
Celcuity reported a net loss of $1.8 million, or $0.26 per share, for the third quarter of 2017, compared to a net loss of $0.9 million,... More
